VLVbio – Liver Health Solutions

CREATING A WORLD WITH NO UNDIAGNOSED LIVER DISEASES

Launch of IMMUNIS Cytokeratin 18F EIA by Institute of Immunology, Japan
VLVbio – Reflecting on a Remarkable Year
XboXLab – Our new partner in the Nordics!
MEDICA Trade Fair

M30 Apoptosense® in NASH

The M30 Apoptosense® ELISA can be used as an aid in diagnosing patients with NASH which would allow for an early identification of patients at risk of developing late stage liver disease and would benefit from specialist care.

Diagnosing NASH also allows an earlier intervention prior to the onset of fibrosis and severe liver injury.

NAFLD NASH ALD ASH DILI ALF ACLF NAFLD NASH ALD ASH DILI ALF ACLF NAFLD NASH ALD ASH DILI ALF ACLF NAFLD NASH ALD ASH DILI ALF ACLF NAFLD NASH ALD ASH DILI ALF ACLF 

NAFLD – a global disease

Non-alcoholic fatty liver disease (NAFLD), a condition where fat accumulates in the liver without the excess consumption of alcohol, has become the most common cause of liver disease in the Western world, and is quickly rising to become the primary cause of liver transplants.

Due to the rise in obesity and diabetes, NAFLD is estimated to affect 30% of the global population, with a high prevalence on all continents.

NASH

NAFLD starts out as steatosis which is an accumulation of fat in the liver and may further progress to non-alcoholic steatohepatitis (NASH), a more serious form of NAFLD, where the liver has become inflamed.

NASH is a potentially fatal condition that affects 5% of the global adult population and can further develop into creation of fibrotic tissue in the liver, with possible cirrhosis as a result.

The right to good health is a fundamental human right. Therefore we strive to offer and facilitate high-quality biomarker assays to detect and measure liver disease in an effective, sensitive and cost-effective way.

Long Experience

Based on antibody technology invented more than 20 years ago at the Karolinska Institute in Sweden, VLVbio has a deep and profound experience within epithelial cell death in different application fields.

Cost-effective and easy to use

Our M30 Apoptosense® ELISA is a non invasive, cost-effective tool for the aid in diagnosing NASH. The M30® can with adequate sensitivity and specificity aid in early detection of NAFLD patients while the disease is still reversible. Our products are easily available globally!

Clinical Validation

In order to validate and pin-point the adequate diagnostic solution in NAFLD healthcare, we are conducting several clinical trials worldwide to evaluate the use of M30 Apoptosense® in NASH diagnosis.

Clinical pharmacology trials

While there are still no FDA or EMA approved drugs for NASH, there are many trials ongoing in different phases to find a pharmaceutical treatment. Our products are used in over 60 active NAFLD trials as a screening tool and endpoint measurement for treatment effect.

Research Collaborations

As part of our mission to aid in finding and validating the best biomarkers to advance towards diagnosis and monitoring of NASH, we are collaborating with large joint governmental collaborations with leading clinical academic centers, regulatory bodies, and the industry. We are currently part of the LITMUS and NAIL-NIT consortiums.

Continuous Innovation

We are committed to satisfying customer requirements for quality, reliability, and support for all of our products. We are dedicated to continuous innovation and improvement in all aspects of our business, constantly looking to improve our products as well as expand our product portfolio.

Our Insights

VIEW ALL INSIGHTS

Do you have any questions or want to learn more about the field?


For U.S. users: The VLVbio K18 assays have not been approved by the U.S. Food and Drug Administration